Literature DB >> 11050291

Ambroxol as an inhibitor of nitric oxide-dependent activation of soluble guanylate cyclase.

I S Severina1, O G Bussygina, N V Pyatakova, Y V Khropov, R A Krasnoperov.   

Abstract

The influence of ambroxol on the activity of human platelet soluble guanylate cyclase and rat lung soluble guanylate cyclase was investigated. Ambroxol in the concentration range from 0.1 to 10 microM had no effect on the basal activity of both enzymes and slightly enhanced it at 50 and 100 microM. Ambroxol inhibited in a concentration-dependent manner the sodium nitroprusside-induced activation of both enzymes. The IC(50) values for inhibition by ambroxol of sodium nitroprusside-stimulated human platelet soluble guanylate cyclase and rat lung soluble guanylate cyclase were 3.9 and 2.1 microM, respectively. Ambroxol did not influence the stimulation of soluble guanylate cyclase by protoporphyrin 1X. Thus, it is possible that the molecular mechanism of the therapeutic action of ambroxol involves the inhibition of nitric oxide (NO)-dependent activation of soluble guanylate cyclase.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11050291     DOI: 10.1016/s0014-2999(00)00739-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  Ambroxol - Resurgence of an old molecule as an anti-inflammatory agent in chronic obstructive airway diseases.

Authors:  P R Gupta
Journal:  Lung India       Date:  2010-04

2.  A simple cost-effective modification improves the quality of immunocytochemical staining in cervical scrape samples characterized by presence of excess mucus.

Authors:  Sagar Pawar; Umesh Mahantshetty; Kedar Deodhar; Tanuja Teni
Journal:  J Histotechnol       Date:  2014-03       Impact factor: 0.714

3.  Enhanced Controlled Transdermal Delivery of Ambroxol from the EVA Matrix.

Authors:  C W Cho; D B Kim; H W Cho; S C Shin
Journal:  Indian J Pharm Sci       Date:  2012-03       Impact factor: 0.975

4.  Ambroxol hydrochloride in the management of idiopathic pulmonary fibrosis: Clinical trials are the need of the hour.

Authors:  P R Gupta
Journal:  Lung India       Date:  2014-01

5.  Ambroxol for the treatment of fibromyalgia: science or fiction?

Authors:  Kai-Uwe Kern; Myriam Schwickert
Journal:  J Pain Res       Date:  2017-08-16       Impact factor: 3.133

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.